Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical
organization headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech
companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2016).
Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and
NBEs (new biological entity). Glenmark has several molecules in various stages of clinical
development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid
arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant
presence in the branded generics markets across emerging economies including India. GPL along with
its subsidiaries operate 17 manufacturing facilities across four countries and has five R&D centers.
The Generics business of Glenmark services the requirements of the US and Western European
markets. The API business sells its products in over 80 countries including the US, EU, South America